Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade
Immunotherapy using checkpoint-blocking antibodies against PD-1 has produced impressive results in a wide range of cancers. However, the response remains heterogeneous among patients. We used noninvasive immuno-positron emission tomography (PET), using 89Zr-labeled PEGylated single-domain antibody f...
Main Author: | Weinberg, Robert A. (Robert Allan) 1942- (Author) |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology (Contributor) |
Format: | Article |
Language: | English |
Published: |
Proceedings of the National Academy of Sciences,
2020-03-30T13:47:53Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
by: Miren Zuazo, et al.
Published: (2020-11-01) -
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01) -
Changing landscape of immuno-oncology: CAR-T therapy and PD1/PDL1 blockade
by: Reddy, Naveen Kumar Munagala
Published: (2016) -
Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021-03-01) -
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
by: Alice L. Hung, et al.
Published: (2018-08-01)